Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review
Annals of Pharmacotherapy · 2026-07 · 60 (7) · 710-714
DOI: 10.1177/10600280251402987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 26.12.2025. Verfasst von Danial Nasim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years. Data sources: A literature search was conducted through October 2025 using PubMed and ClinicalTrials.gov with the terms “lebrikizumab,” “Ebglyss,” “lebrikizumab clinical trials,” and “lebrikizumab atopic dermatitis.” Phase I to III clinical trials, post-approval studies, and FDA package insert were reviewed. Study selection and data extraction: Trials evaluating lebrikizumab in patients with AD were included. Data were extracted on study design, pharmacology, efficacy outcomes, and safety events. One phase I, 2 phase II, and 6 phase III studies were summarized along with real-world evidence. Data synthesis: Lebrikizumab had dose-dependent reductions in AD severity and pruritus, with improvements observed as early as day 2. Across phase III trials, 33% to 43% of lebrikizumab-treated patients achieved an Investigator’s Global Assessment Score (IGA) 0/1 compared with 11% or less with placebo. Adverse events were mild; conjunctivitis occurred less frequently than with agents targeting both IL-4 and IL-13. Relevance to patient care and clinical practice in comparison to existing drugs: As a selective IL-13 inhibitor, lebrikizumab offers comparable efficacy with reduced ocular adverse events relative to dupilumab. Its pharmacologic distinctions from tralokinumab may carry clinical implications.
Conclusion
Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
ORCID-Profile: Danial Nasim
Zitieren
APA
Nasim, D., Shaffer, B., & Feldman, S. R. (2026). Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review. Annals of Pharmacotherapy, 60(7), 710-714. https://doi.org/10.1177/10600280251402987
Vancouver
Nasim D, Shaffer B, Feldman SR. Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review. Annals of Pharmacotherapy. 2026;60(7):710-714. doi:10.1177/10600280251402987
BibTeX
@article{Nasim2026,
author = {Nasim, Danial and Shaffer, Brett and Feldman, Steven R},
title = {Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review},
journal = {Annals of Pharmacotherapy},
year = {2026},
volume = {60},
number = {7},
pages = {710--714},
doi = {10.1177/10600280251402987}
}
EUVIMED